Brief: QED And Parent Company Bridgebio Announce Preclinical Data Supporting Tolerability And Activity Of Low-Dose Infigratinib In Treating Achondroplasia

Qed Connect

17/10/2019 12:05

Oct 17 (Reuters) - BridgeBio Pharma Inc  BBIO.O :
    * QED AND PARENT COMPANY BRIDGEBIO ANNOUNCE PRECLINICAL DATA
SUPPORTING TOLERABILITY AND ACTIVITY OF LOW-DOSE INFIGRATINIB IN
TREATING ACHONDROPLASIA

Source text for Eikon:  ID:nPn3M6VHNa 
Further company coverage:  BBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))